Tetrahydronicotyrine, Dl-
Brand names,
Tetrahydronicotyrine, Dl-
Analogs
Tetrahydronicotyrine, Dl-
Brand Names Mixture
Tetrahydronicotyrine, Dl-
Chemical_Formula
C10H14N2
Tetrahydronicotyrine, Dl-
RX_link
http://www.rxlist.com/cgi/generic2/nicotini.htm
Tetrahydronicotyrine, Dl-
fda sheet
Tetrahydronicotyrine, Dl-
msds (material safety sheet)
Tetrahydronicotyrine, Dl-
Synthesis Reference
Pinner, Ber. 26, 294 (1893)
Tetrahydronicotyrine, Dl-
Molecular Weight
162.232 g/mol
Tetrahydronicotyrine, Dl-
Melting Point
-79 oC
Tetrahydronicotyrine, Dl-
H2O Solubility
1 g/mL
Tetrahydronicotyrine, Dl-
State
Liquid
Tetrahydronicotyrine, Dl-
LogP
1.305
Tetrahydronicotyrine, Dl-
Dosage Forms
Gum; Inhaler; Patch
Tetrahydronicotyrine, Dl-
Indication
For the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.
Tetrahydronicotyrine, Dl-
Pharmacology
Nicotine, the primary alkaloid in tobacco products binds stereo-selectively to nicotinic-cholinergic receptors on autonomic ganglia, the adrenal medulla, neuromuscular junctions and in the brain. Nicotine exerts two effects, a stimulant effect exerted at the locus ceruleus and a reward effect in the limbic system. Itranvenous administration of nicotine causes release of acetylcholine, norepinephrine, dopamine, serotonine, vasopressin, beta-endorphin and ACTH. Nicotine is a highly addictive substance. Nicotine also induces peripheral vasoconstriction, tachycardia and elevated blood pressure. Nicotine inhalers and patches are used to treat smoking withdrawl syndrome. Nicotine is classified as a stimulant of autonomic ganglia.
Tetrahydronicotyrine, Dl-
Absorption
Absorption of nicotine through the buccal mucosa is relatively slow and the high and rapid rise followed by the decline in nicotine arterial plasma concentrations seen with cigarette smoking are not achieved with the inhaler. About 10% of absorbed nicotine is excreted unchanged in urine.
Tetrahydronicotyrine, Dl-
side effects and Toxicity
Symptoms of overdose include nausea, abdominal pain, vomiting, diarrhea, diaphoresis, flushing, dizziness, disturbed hearing and vision, confusion, weakness, palpitations, altered respiration and hypotension. LD50= 24 mg/kg (orally in mice).
Tetrahydronicotyrine, Dl-
Patient Information
A patient information sheet is included in the package of NICOTROL Inhaler cartridges dispensed to the patient.
Patients should be encouraged to read the information sheet carefully and to ask their physician and pharmacist about
the proper use of the product .
Patients must be advised to keep both used and unused cartridges out of the reach of children and pets.
Tetrahydronicotyrine, Dl-
Organisms Affected
Humans and other mammals